title: [Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases].
abstract: OBJECTIVE
  To evaluate the cost-effectiveness of samarium [153Sm-EDTMP] (Quadramet) compared to conventional therapy in the treatment of pain in patients with prostate cancer and bone metastases.
  
  
  METHODS
  A decision tree model for the treatment of bone pain due to metastases was adapted to the Spanish context. The model represents the standard treatment patterns in Spain for the study population. The time-course of the model is 4 months and it computes an estimate for the cost of pain control per patient. The effectiveness data for the model derive from a randomised trial. The current treatment patterns have been established according to the consensus opinions of a group of medical experts.
  
  
  RESULTS
  The cost of pain control per patient is euro 12,515.39 for conventional therapy and euro 5,595.52 for samarium-153 (Quadramet) therapy. The incremental cost-effectiveness analysis shows that samarium-153 (Quadramet) is a dominant therapy. It presents lower costs and higher efficacy than the conventional strategy. The sensitivity analyses showed these results to be robust.
  
  
  CONCLUSIONS
  Samarium-153 (Quadramet) is cost-effective in treating pain in patients with prostate cancer and bone metastases.
authors.affiliation: SOIKOS, Centro de Estudios en Economía de la Salud y de la Política Social, S.L., Barcelona, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Velasco Latrás
authors.forename: Luis
authors.initials: L
authors.lastname: Carreras Coderch
authors.forename: Fernando
authors.initials: F
authors.lastname: Antoñanzas Villar
authors.forename: Juan
authors.initials: J
authors.lastname: Coya Viña
authors.forename: José
authors.initials: J
authors.lastname: Martín Comín
authors.forename: Francisco
authors.initials: F
authors.lastname: Martínez Carderón
authors.forename: José
authors.initials: J
authors.lastname: Nieto Martín-Bejarano
authors.forename: Alberto
authors.initials: A
authors.lastname: Sáenz Cusí
authors.forename: Gala
authors.initials: G
authors.lastname: Serrano Bermúdez
authors.forename: Amaya
authors.initials: A
authors.lastname: Echevarría Icaza
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000191:economics* / Q000556:secondary; D018712:Analgesics, Non-Narcotic / Q000191:economics* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000556:secondary; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D008297:Male; D018803:Models, Economic; D009942:Organometallic Compounds / Q000191:economics* / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000191:economics* / Q000627:therapeutic use; D010147:Pain Measurement / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000473:pathology; D011868:Radioisotopes / Q000191:economics*; D012493:Samarium / Q000191:economics; D016896:Treatment Outcome
chemical_list: D018712:Analgesics, Non-Narcotic; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D012493:Samarium; C061972:samarium Sm-153 lexidronam